Investigational Drug Information for BAY1817080
✉ Email this page to a colleague
What is the drug development status for BAY1817080?
BAY1817080 is an investigational drug.
There have been 14 clinical trials for BAY1817080.
The most recent clinical trial was a Phase 2 trial, which was initiated on October 2nd 2020.
The most common disease conditions in clinical trials are Endometriosis, Urinary Bladder, Overactive, and Neuralgia. The leading clinical trial sponsors are Bayer and [disabled in preview].
There are four US patents protecting this investigational drug and seventy-one international patents.
Summary for BAY1817080
| US Patents | 4 |
| International Patents | 71 |
| US Patent Applications | 18 |
| WIPO Patent Applications | 5 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2020-10-02) |
| Vendors | 19 |
Recent Clinical Trials for BAY1817080
| Title | Sponsor | Phase |
|---|---|---|
| A Trial to Learn How BAY1817080 Moves Into, Through and Out of the Body and How Safe it is in Healthy Chinese Men | Bayer | Phase 1 |
| Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive Pill (Placebo) and Elagolix in Women Suffering From Pain Related to a Condition Where the Tissue That Usually | Bayer | Phase 2 |
| A 2-part Trial to Learn More About How BAY1817080 Works, How Safe it is, and What the Right Dose is for Participants With Diabetic Neuropathic Pain | Bayer | Phase 2 |
Clinical Trial Summary for BAY1817080
Top disease conditions for BAY1817080
Top clinical trial sponsors for BAY1817080
US Patents for BAY1817080
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| BAY1817080 | ⤷ Subscribe | 1,3-thiazol-2-yl substituted benzamides | BEYER AKTIENGESELLSCHAFT (Leverkusen, DE) | ⤷ Subscribe |
| BAY1817080 | ⤷ Subscribe | 1,3-thiazol-2-yl substituted benzamides | Bayer Aktiengesellschaft (Leverkusen, DE) | ⤷ Subscribe |
| BAY1817080 | ⤷ Subscribe | 1,3-thiazol-2-yl substituted benzamides | Bayer Aktiengesellschaft (Leverkusen, DE) | ⤷ Subscribe |
| BAY1817080 | ⤷ Subscribe | 1,3-thiazol-2-yl substituted benzamides | Bayer Aktiengesellschaft (Leverkusen, DE) | ⤷ Subscribe |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for BAY1817080
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| BAY1817080 | Argentina | AR102948 | 2034-12-09 | ⤷ Subscribe |
| BAY1817080 | Argentina | AR119761 | 2034-12-09 | ⤷ Subscribe |
| BAY1817080 | Australia | AU2015359626 | 2034-12-09 | ⤷ Subscribe |
| BAY1817080 | Brazil | BR112017012327 | 2034-12-09 | ⤷ Subscribe |
| BAY1817080 | Canada | CA2969952 | 2034-12-09 | ⤷ Subscribe |
| BAY1817080 | Chile | CL2017001488 | 2034-12-09 | ⤷ Subscribe |
| BAY1817080 | China | CN107207507 | 2034-12-09 | ⤷ Subscribe |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
